Pharmaceuticals, Biotechnology and Life Sciences
OptiBiotix Health, a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, finished first half of trading with sales of £351k, compared to the year 2022 sales of the same period, of £119k, which is a 195% increase over, the company said in its unaudited results for the six months ended 30 June 2023.
Hemogenyx Pharmaceuticals, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, committed to progressing HEMO CAR-T to clinical trials as the its next step.
The US Food and Drug Administration (FDA) has granted Germany based 4SC’s application for Orphan Drug Designation for resminostat (Kinselby) for cutaneous T cell lymphoma (CTCL), the company said in a press release on Wednesday.
The life science group Sartorius and a UK-based startup SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles for biopharmaceutical drugs.
The two investors are already partners on the Danish biotech scene, and this new investment underlines Lundbeckfonden BioCapital’s longstanding commitment to Danish science and the local biotech ecosystem.
Japan’s Ministry of Health, Labour and Welfare has approved GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults.
MC2 Therapeutics has acquired option rights from Regranion, LLC to exclusively license Regranion’s RGRN-305 for the treatment of all human…
As part of a collaborative working agreement between United Lincolnshire Hospitals NHS Trust and pharmaceutical company Boehringer Ingelheim, a new cardio-diabetic outpatient service has been launched to help reduce recurring heart attacks in people with diabetes.
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Adtralza tralokinumab in a new pre-filled pen, following the European Commission (EU) decision on the 1st of September 2023. The pre-filled pen will be available in the UK for tralokinumab patients from early 2024.